Cargando…

Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study

Telbivudine (LdT) is an orally l-nucleoside with potent and specific antihepatitis B virus (HBV) activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion of LdT treatment than other anti-HBV agents suggests a potential immunomodulatory effect. The aim of the study was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiaoling, Li, Jia, Liu, Jie, Gao, Min, Zhou, Li, Lu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466219/ https://www.ncbi.nlm.nih.gov/pubmed/28591041 http://dx.doi.org/10.1097/MD.0000000000007064

Ejemplares similares

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
por: Zhang, Yang, et al.
Publicado: (2019)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase
por: Li, Ling, et al.
Publicado: (2021)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis
por: Banerjee, S., et al.
Publicado: (2016)

Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy
por: Geng, Yan, et al.
Publicado: (2016)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
por: Hadziyannis, Emilia, et al.
Publicado: (2018)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis
por: Xing, Tongjing, et al.
Publicado: (2017)

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
por: Su, Tung-Hung, et al.
Publicado: (2013)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics
por: Kramvis, Anna
Publicado: (2016)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma
por: Padarath, Kiyasha, et al.
Publicado: (2023)

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
por: Gan, Weiqiang, et al.
Publicado: (2020)

Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment
por: Yang, Jiezuan, et al.
Publicado: (2017)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013)

Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
por: Liang, Jian, et al.
Publicado: (2013)

Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients
por: Papachrysos, Nikolaos, et al.
Publicado: (2015)

Antiviral therapy leads to histological improvement in HBeAg-negative chronic hepatitis B patients
por: Basyigit, Sebahat, et al.
Publicado: (2015)

Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: A community-based study
por: Chen, Ping, et al.
Publicado: (2017)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
por: Bonino, Ferruccio, et al.
Publicado: (2022)

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
por: Zhang, Zhan-qing, et al.
Publicado: (2019)

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
por: Lee, Soon Kyu, et al.
Publicado: (2023)

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
por: Zeng, Yu-Li, et al.
Publicado: (2021)

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues
por: Broquetas, Teresa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lmnmgrku88p98up3o0qju727ff